StreetAlpha.app
Home › Stocks › CMPX

Compass Therapeutics, Inc. (CMPX)

Healthcare
$0.61
▼ −8.28%
LAST CLOSE · NOV 17

Compass Therapeutics is a Boston biopharmaceutical company developing antibody drugs to treat cancer. It last closed at $0.61 on Nov 17, down 8.28% on the day. The average 12-month price target from 5 analysts is $5.78 (+852.7% from the last close), with a high of $12.00 and a low of $0.90. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell).

AI Auto Pilots
Is CMPX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$86.4M
EPS (diluted)
−$0.46
Free cash flow
−$61.9M
Valuation
Market cap
$109.3M
180.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.5M
At Sep 30
Shareholder equity
$142.6M
Shares outstanding
180.1M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $850K$850KFY2024FY2025: $0$0FY2025

From CMPX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
4 Buy1 Hold0 Sell
Each firm's latest rating on CMPX in the past 90 days
Average 12-month target
$5.78
▲ 852.7% upside

Based on 5 analysts who set a price target on CMPX in the past 90 days. The average target is $5.78, with a high of $12.00 and a low of $0.90, compared with the last close of $0.61.

Low $0.90Avg $5.78High $12.00
Blue marker: last close $0.61
Highest target$12.00
Average target$5.78
Lowest target$0.90
Latest rating changes
WedbushTarget lowered
Nov 10Hold$1 → $0.90
Craig-HallumMaintained
Sep 23Buy$8
CitizensMaintained
Sep 23Buy$4
GuggenheimMaintained
Sep 23Buy$4
WedbushDowngrade
Sep 23Hold$1
DateFirmActionRatingPrice target
Nov 10WedbushTarget loweredHold$1 → $0.90
Sep 23Craig-HallumMaintainedBuy$8
Sep 23CitizensMaintainedBuy$4
Sep 23GuggenheimMaintainedBuy$4
Sep 23WedbushDowngradeHold$1
Loading…

Technical Analysis

CMPX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 26% below its 20 day and 76% below its 50 day average. It is 373% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $0.57, and the nearest resistance the Pivot at $0.61.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.1%/day
Key levels
$6.8852 week high+1027.9%
$2.87200 day average+370.5%
$1.64100 day average+168.9%
$1.0750 day average+75.4%
$0.81Swing high (Nov 2)+32.8%
$0.7620 day average+24.6%
$0.65Pivot R1+6.6%
$0.61Pivot+0.0%
$0.61Last close
$0.5752 week low−6.6%
$0.56Pivot S1−8.2%
Indicators
RSI (14)27.01Oversold below 30Oversold
MACD-0.10Above its signal lineBullish
Stochastic19.2Near the bottom of its rangeOversold
ADX (14)45.8Strong downtrend
Williams %R-88.7Oversold below −80, overbought above −20Oversold
CCI (20)-286.4Oversold below −100, overbought above 100Oversold
Rate of change−20.7%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 12.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CMPX

What happened before

See how CMPX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CMPX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CMPX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CMPX in the last 90 days.

Loading…

See today’s whale options flow across the market →

CMPX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼66 buying vs 141 selling
  • ▼Held by funds -2.8 pts
  • ▼Funds holding -44
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding173217−20.3%
In funds' top 10110.0%
Held by funds89.2%92.0%−2.8 pts
New / increased20 / 4663 / 85−55.4%
Reduced / sold out79 / 6244 / 48+53.3%
Put/call ratio0.420.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CMPX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CMPX is in one of them and how their past CMPX trades turned out.

CMPX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CMPX in an article yet. Here's the latest on the wider market.

About Compass Therapeutics

Compass Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that develops antibody drugs for cancer. Its lead candidate, tovecimig, is designed to block two signaling pathways that tumors use to grow new blood vessels, and it is being tested in patients with biliary tract cancer. The company also has three other clinical stage candidates that target immune system pathways, including CD137 and PD-1. None of these candidates has been approved for sale.

Headquarters
Boston, MA